Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva Pharmaceutical (NYSE: TEVA) received FDA approval for WELTRUZA, a monthly schizophrenia injectable. The drug will be priced at $2,950 and launched using the existing UZEDY sales infrastructure. Teva expects initial uptake from oral olanzapine users and aims for 85% payer coverage within a year. The company forecasts combined revenue of $1.5B-$2B for UZEDY and WELTRUZA, with meaningful WELTRUZA revenue expected in the second half of the following year.
How this was made
The 30-second read
Why it matters
The approval creates a new growth catalyst for Teva, potentially improving earnings outlook.
Market read
First FDA approval for a new schizophrenia injectable; likely to move TEVA stock.
What to watch
Potential competition from other long‑acting antipsychotics and the need for Medicaid formulary acceptance.
Background
Teva's WELTRUZA is priced at $2,950 wholesale acquisition cost and will launch using existing commercial infrastructure.
Ticker impact
Teva received FDA approval for its new monthly schizophrenia injectable WELTRUZA, a first-in-class product.
likely upward pressure as investors price in the new product launch
FDA clearance is a material regulatory event; the drug targets a large market and the company expects meaningful revenue in H2.
Market effects
Strengthens the psychiatric drug segment and may benefit peers with similar pipelines.
Positive for US pharma stocks, especially those with FDA pipelines.
Adds to global biotech momentum, could influence investor sentiment toward emerging drug approvals.
Counterpoint
If payer coverage delays materialize, the revenue upside could be slower than expected.
Key entities
- companyTeva Pharmaceutical Industries
Global pharma company receiving FDA approval.
